Navigation Links
WorldHeart Appoints New President and CEO

SALT LAKE CITY, Feb. 6 /PRNewswire-FirstCall/ -- World Heart Corporation ("WorldHeart", Nasdaq: WHRT), a pioneer in cardiac assist technologies, announced today that it has appointed John Alexander ("Alex") Martin as President and CEO. Mr. Martin also replaced Jal S. Jassawalla on the Board of Directors. Mr. Martin joins WorldHeart from Edwards Lifesciences where he was President of the North American Region and Corporate Vice President since 2004. Previously, Alex was with Cordis Corporation, a Johnson and Johnson (J&J) company, where he served as Senior Vice President of International and prior to that, Vice President of Sales and Marketing. At Cordis, he had responsibility for all U.S. coronary therapeutic and diagnostic device sales and under his leadership the company experienced significant growth and became the market leader. Alex was responsible for the launch of the first commercialized drug-eluting stent in the US while at Cordis.

Before Cordis, Mr. Martin, 55, served in sales, marketing and business development management positions at several organizations, including C.R. Bards' USCI division, Cambridge Heart and IMED Corporation. He also served as Director of the Emergency Medical Services at The Medical Center at Bowling Green. Mr. Martin earned a bachelor's degree from the University of Kentucky at Lexington.

Jal S. Jassawalla, WorldHeart's President and CEO since 2004 and co-founder of the original Novacor Medical Corporation, commented that, "I join WorldHeart's Board of Directors and employees in welcoming Alex to WorldHeart and the exciting and promising field of circulatory assist therapy." Mr. Jassawalla will continue in a senior role as Executive Vice President and Chief Technology Officer. His emphasis will be on research & development, product strategy, and clinical and regulatory affairs.

"We are pleased to have Alex Martin join WorldHeart," said Michael Estes, Chair of WorldHeart's Board of Directors. "Alex's extensive background in medical technologies and long-standing relationships within the cardiovascular community will be particularly valuable as WorldHeart brings its Levacor technology into the clinical arena and continues to advance its unique 'mag-lev' technology platform. The Board of Directors is also very pleased that Jal Jassawalla will continue in his key role as Executive Vice President of WorldHeart."

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. WorldHeart is headquartered in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements regarding WorldHeart's technology platform and reliance on key executives, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development and market acceptance of and demand for WorldHeart's products; delisting from the NASDAQ Stock Market if compliance with the listing standards is not regained; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB/A for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2008 and September 30, 2008.

SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
2. WorldHeart Regains Compliance With the Minimum Bid Price Rule
3. WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7)
4. WorldHeart Announces Effectiveness of Reverse Stock Split
5. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
6. WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market
7. WorldHeart Announces Voluntary Delisting from the Toronto Stock Exchange
8. WorldHeart Announces Possible Delisting Action by NASDAQ
9. WorldHeart Notified of TSX Delisting Review
10. WorldHeart Appoints David Pellone Chief Financial Officer
11. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
Post Your Comments:
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is ... Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College ... as only one of twelve colleges and universities in the state of California make ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... Express Travel Representative. As a franchise owner, Somu now offers travelers, value and ... destination wedding packages, private cruise sales, as well as, cabin upgrades and special ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the ... 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the ... Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention Center ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology: